The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
March 30, 2010
Share this post
2 Comments

Law Bytes
Episode 241: Scott Benzie on How Government Policy Eroded Big Tech Support for Canadian Culture
byMichael Geist

July 21, 2025
Michael Geist
June 30, 2025
Michael Geist
June 23, 2025
Michael Geist
Search Results placeholder
Recent Posts
The Sound of Silence: On Being Jewish in Canada in 2025
The Law Bytes Podcast, Episode 241: Scott Benzie on How Government Policy Has Eroded Big Tech Support for Canadian Culture
What Is the Canadian Government Doing With Its Incoherent Approach to TikTok?
The Law Bytes Podcast, Episode 240: Dean Beeby on Why Canada’s Language Laws May Stop Government From Posting Access to Information Records Online
Risky Business: The Legal and Privacy Concerns of Mandatory Age Verification Technologies
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.